Cyclizing a cone snail venom peptide made it resistant to breakdown in human blood and up to 52 times more potent at a key brain receptor, while retaining its original muscle-receptor activity.
52-fold potency increaseCyclizing the venom peptide unexpectedly increased its potency at the neuronal α3β2 nicotinic receptor by up to 52 times, reaching an IC50 of 1.3 nM
What the researchers found
Backbone cyclization of α-conotoxin CIA produced analogues that retained low nanomolar potency at muscle-type nicotinic receptors while gaining up to 52-fold higher potency at the neuronal α3β2 subtype (IC50 1.3 nM). The cyclic analogues also showed greatly improved resistance to degradation in human serum. When tested in zebrafish, the peptides were highly paralytic both by injection (adults) and bath application (larvae), demonstrating barrier-crossing ability and efficient uptake — unusual properties for peptides of this size.
Why it matters
Venom peptides are a rich source of potential drugs, but their clinical use is typically limited by rapid breakdown in the body and poor absorption. This study shows that a simple chemical modification — connecting the peptide's backbone into a loop — can simultaneously solve stability problems and unexpectedly enhance potency at a key receptor subtype. This approach could be broadly applied to other venom-derived peptide drug candidates.
How the study worked
Researchers designed cyclic analogues of α-conotoxin CIA using backbone cyclization. They tested the analogues' potency against muscle-type and neuronal (α3β2) nicotinic acetylcholine receptors, measured their stability in human serum, determined their 3D structures using NMR spectroscopy, and assessed their biological activity in vivo using zebrafish injection and bath application models.
What this study cannot tell us
The in vivo testing was limited to zebrafish models, which, while useful for demonstrating bioactivity and barrier crossing, do not directly predict mammalian pharmacokinetics or therapeutic potential. No mammalian in vivo studies were reported. The structural explanations for the gain in α3β2 potency are based on NMR comparison and remain speculative without co-crystal structures with the receptor.
How to read the evidence
This is a preclinical laboratory study combining in vitro receptor binding assays, structural biology (NMR), serum stability testing, and in vivo zebrafish models. It provides strong mechanistic and proof-of-concept data but has not been tested in mammalian models or clinical settings.
When this study was published
Published in 2020, this study represents current approaches in peptide medicinal chemistry and venom-based drug discovery. The backbone cyclization strategy it validates continues to be actively explored in the field.
The bigger picture
Venom-derived peptides represent a vast library of naturally evolved drug-like molecules — there are already approved drugs based on cone snail toxins (e.g., ziconotide for pain). This study demonstrates that backbone cyclization can simultaneously improve two of the biggest barriers to peptide drug development: metabolic stability and receptor potency. The unexpected gain in neuronal receptor activity also suggests that cyclization may reveal hidden pharmacological profiles in venom peptides, opening new therapeutic possibilities.
Questions still open
- Would these cyclic conotoxin analogues show similar stability and potency improvements in mammalian models, and could they be developed as pain therapeutics targeting nicotinic receptors?
- Can backbone cyclization be systematically applied to other conotoxins and venom peptides to improve their drug-like properties?
- What is the structural basis for the unexpected 52-fold potency gain at the α3β2 receptor — could this be exploited for subtype-selective drug design?
Common questions
What is backbone cyclization and why does it help peptide drugs?
Are cone snail venom peptides used as real drugs?
Read the original research
Backbone Cyclization Turns a Venom Peptide into a Stable and Equipotent Ligand at Both Muscle and Neuronal Nicotinic Receptors.
Journal of medicinal chemistry, 63(21), 12682-12692
Citation
Giribaldi, Julien; Haufe, Yves; Evans, Edward R J; Amar, Muriel; Durner, Anna; Schmidt, Casey; Faucherre, Adèle; Moha Ou Maati, Hamid; Enjalbal, Christine; Molgó, Jordi; Servent, Denis; Wilson, David T; Daly, Norelle L; Nicke, Annette; Dutertre, Sébastien. (2020). Backbone Cyclization Turns a Venom Peptide into a Stable and Equipotent Ligand at Both Muscle and Neuronal Nicotinic Receptors.. Journal of medicinal chemistry, 63(21), 12682-12692. https://doi.org/10.1021/acs.jmedchem.0c00957